Physician profile
Daphne E Evans
NPI 1740342930
$1,415.02
in general payments reported to CMS, 2019-2025
21 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.67 · 2024: $61.21 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $214.45 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit, Aveir |
| Bridgebio Pharma, INC. | $206.83 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $195.06 | 2025 | Amvuttra |
| Heartflow, INC. | $177.29 | 2025 | |
| Glaxosmithkline, LLC. | $77.71 | 2025 | Shingrix, Arexvy |
| Pfizer INC. | $77.52 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $73.91 | 2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $60.32 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $46.91 | 2025 | Verquvo |
| Kestra Medical Technology Services, INC. | $36.45 | 2025 | Assure Wcd |
| Scpharmaceuticals INC. | $27.56 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.62 | 2025 | Jardiance |
| Celgene Corporation | $24.32 | 2025 | Camzyos |
| Astrazeneca Pharmaceuticals Lp | $24.13 | 2025 | Farxiga |
| Chiesi USA, INC. | $24.00 | 2024 | Juxtapid |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $22.88 | 2025 | Ozempic |
| Edwards Lifesciences Corporation | $21.98 | 2025 | Sapien 3 Ultra Resilia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.40 | 2025 | Lifevest |
| Lilly USA, LLC | $21.34 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $18.21 | 2025 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $18.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daphne Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.